Financial Performance - MetaVia reported a net loss of $3.4 million, or $0.14 per share, for Q3 2025, compared to a net loss of $5.7 million, or $0.55 per share, in Q3 2024[10] - The net loss for the three months ended September 30, 2025, was $3,377 million, compared to a net loss of $5,652 million for the same period in 2024, indicating an improvement of about 40.2%[19] - Loss per share improved from $(0.55) in Q3 2024 to $(0.14) in Q3 2025, reflecting a significant reduction in losses per share[19] - The company reported a loss before income taxes of $3,377 million for Q3 2025, compared to a loss of $5,652 million in Q3 2024, showing a reduction of about 40.2%[19] Expenses - Research and Development (R&D) expenses decreased to approximately $1.9 million in Q3 2025 from $4.5 million in Q3 2024, a reduction of about 58%[7] - Total operating expenses for Q3 2025 were approximately $3.5 million, down from $6.3 million in Q3 2024, reflecting a decrease of approximately 44%[10] - R&D expenses for the nine months ended September 30, 2025, were approximately $6.6 million, compared to $17.5 million for the same period in 2024, a decrease of about 62%[7] - General and Administrative (G&A) expenses for Q3 2025 were approximately $1.6 million, slightly down from $1.7 million in Q3 2024[10] - General and administrative expenses decreased from $1,742 million in Q3 2024 to $1,561 million in Q3 2025, a reduction of approximately 10.4%[19] Income and Assets - Total other income for Q3 2025 was approximately $0.1 million, down from $0.6 million in Q3 2024, primarily due to lower interest income[10] - Other income for the three months ended September 30, 2025, was $98 million, down from $607 million in Q3 2024, a decrease of approximately 83.8%[19] - Total assets decreased from $16,260 million as of December 31, 2024, to $14,765 million as of September 30, 2025, representing a decline of approximately 9.2%[18] - Total stockholders' equity decreased from $7,931 million as of December 31, 2024, to $6,331 million as of September 30, 2025, a decline of approximately 20.2%[18] Shareholder Information - The weighted average shares of common stock increased from 10,214,087 in Q3 2024 to 24,415,876 in Q3 2025, indicating a significant increase in shares outstanding[19] Clinical Trials and Future Plans - The Phase 1 clinical trial for DA-1726 showed a mean body-weight reduction of up to 6.3% and waist circumference reduction of up to 3.9 inches after four weeks of treatment[3] - The company is preparing for an end-of-Phase 2 meeting with the FDA for vanoglipel (DA-1241) in the first half of 2026[8] - The company expects to report results from the 8-week, 48 mg cohort of the Phase 1 study by year-end 2025[8]
NeuroBo Pharmaceuticals(NRBO) - 2025 Q3 - Quarterly Results